日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Combination Treatment with Intravesical Interferon-Alpha Gene Therapy and Oral Pan-ErbB Receptor Family Blocker Improves Survival in Mice with Bladder Cancer

膀胱内注射干扰素-α基因疗法联合口服泛ErbB受体家族阻滞剂可提高膀胱癌小鼠的生存率

Sood, Akshay; Martini, Alberto; Rudzinski, Jan K; Tholomier, Come; Contieri, Roberto; Lee, I-Ling; Parker, Nigel R; Yla-Herttuala, Seppo; McConkey, David J; Dinney, Colin P N; Mokkapati, Sharada

Oncolytic immunotherapy with nivolumab in muscle-invasive bladder cancer: a phase 1b trial.

纳武利尤单抗溶瘤免疫疗法治疗肌层浸润性膀胱癌:一项 1b 期试验

Li Roger, Villa Nancy Y, Yu Xiaoqing, Johnson Joseph O, Borjas Gustavo, Dhillon Jasreman, Moran-Segura Carlos M, Kim Youngchul, Francis Natasha, Dorman Denise, Powers John J, Sexton Wade J, Spiess Philippe E, Poch Michael A, Zemp Logan, Gilbert Scott M, Zhang Jingsong, Pow-Sang Julio M, Anderson Alexander R A, Li Tingyi, Wang Xuefeng, Grass G Daniel, Burke James M, Dinney Colin P N, Rodriguez Paulo C, Jain Rohit K, Mulé James J, Conejo-Garcia Jose R

Predicting response to neoadjuvant chemotherapy in muscle-invasive bladder cancer via interpretable multimodal deep learning

利用可解释的多模态深度学习预测肌层浸润性膀胱癌对新辅助化疗的反应

Bai, Zilong; Osman, Mohamed; Brendel, Matthew; Tangen, Catherine M; Flaig, Thomas W; Thompson, Ian M; Plets, Melissa; Scott Lucia, M; Theodorescu, Dan; Gustafson, Daniel; Daneshmand, Siamak; Meeks, Joshua J; Choi, Woonyoung; Dinney, Colin P N; Elemento, Olivier; Lerner, Seth P; McConkey, David J; Faltas, Bishoy M; Wang, Fei

Intravesical interferon-α2b gene therapy with nadofaragene firadenovec-vncg: a contemporary review

膀胱内注射干扰素-α2b基因疗法联合nadofaragene firadenovec-vncg:最新综述

Lee, Taeweon; Gianchandani, Ayushi; Boorjian, Stephen A; Shore, Neal D; Narayan, Vikram M; Dinney, Colin P N; Kamat, Ashish M

Efficacy of Intravesical Nadofaragene Firadenovec for Patients With Bacillus Calmette-Guérin-Unresponsive Nonmuscle-Invasive Bladder Cancer: 5-Year Follow-Up From a Phase 3 Trial

膀胱内灌注纳多法拉根·菲拉德诺维克治疗卡介苗无反应性非肌层浸润性膀胱癌患者的疗效:一项3期试验的5年随访结果

Narayan, Vikram M; Boorjian, Stephen A; Alemozaffar, Mehrdad; Konety, Badrinath R; Shore, Neal D; Gomella, Leonard G; Kamat, Ashish M; Bivalacqua, Trinity J; Montgomery, Jeffrey S; Lerner, Seth P; Busby, Joseph E; Poch, Michael; Crispen, Paul L; Steinberg, Gary D; Schuckman, Anne K; Downs, Tracy M; Mashni, Joseph Jr; Lane, Brian R; Guzzo, Thomas J; Bratslavsky, Gennady; Karsh, Lawrence I; Woods, Michael E; Brown, Gordon; Canter, Daniel; Luchey, Adam; Lotan, Yair; Inman, Brant A; Williams, Michael B; Cookson, Michael S; Chang, Sam S; Sankin, Alexander I; O'Donnell, Michael A; Sawutz, David; Philipson, Richard; Parker, Nigel R; Yla-Herttuala, Seppo; Rehm, Dorte; Jakobsen, Jørn S; Juul, Kristian; Dinney, Colin P N

DNA Damage Response Alterations Predict for Neoadjuvant Chemotherapy Sensitivity in Muscle-Invasive Bladder Cancer: A Correlative Analysis of the SWOG S1314 Trial

DNA损伤反应改变可预测肌层浸润性膀胱癌新辅助化疗的敏感性:SWOG S1314试验的相关性分析

Iyer, Gopa; Tangen, Catherine M; Sarfaty, Michal; Regazzi, Ashley M; Lee, I-Ling; Fong, Megan; Choi, Woonyoung; Dinney, Colin P N; Flaig, Thomas W; Thompson, Ian M Jr; Lerner, Seth P; McConkey, David J; Rosenberg, Jonathan E

A Pilot Study of the CD38 Antagonist Daratumumab in Patients with Metastatic Renal Cell Carcinoma or Muscle-Invasive Bladder Cancer

CD38拮抗剂达雷妥尤单抗治疗转移性肾细胞癌或肌层浸润性膀胱癌患者的初步研究

Campbell, Matthew T; Shah, Amishi Y; Msaouel, Pavlos; Tannir, Nizar M; Siefker-Radtke, Arlene O; Kamat, Ashish M; Navai, Neema; Dinney, Colin P N; Rao, Priya; Guo, Charles C; Sheth, Rahul A; Venkatesan, Aradhana M; Tidwell, Rebecca S; Yadav, Shalini S; Gu, Aidi; Chen, Hong; Macaluso, Marc; Duan, Fei; Basu, Sreyashi; Jindal, Sonali; Sharma, Padmanee

Correlative Analysis of ATM, RB1, ERCC2, and FANCC Mutations and Pathologic Complete Response After Neoadjuvant Chemotherapy in Patients with Muscle-invasive Bladder Cancer: Results from the SWOG S1314 Trial

ATM、RB1、ERCC2 和 FANCC 突变与肌层浸润性膀胱癌患者新辅助化疗后病理完全缓解的相关性分析:来自 SWOG S1314 试验的结果

Plimack, Elizabeth R; Tangen, Catherine; Plets, Melissa; Kokate, Rutika; Xiu, Joanne; Nabhan, Chadi; Ross, Eric A; Grundy, Erin; Choi, Woonyoung; Dinney, Colin P N; Lee, I-Ling C; Fong, Megan; Scott Lucia, M; Daneshmand, Siamak; Theodorescu, Dan; Goldkorn, Amir; Lerner, Seth P; Flaig, Thomas W; McConkey, David J

Interferon gene therapy with nadofaragene firadenovec for bladder cancer: from bench to approval

干扰素基因疗法联合纳多法拉基因菲拉德诺韦克治疗膀胱癌:从实验室到获批

Martini, Alberto; Tholomier, Côme; Mokkapati, Sharada; Dinney, Colin P N

Antiadenovirus Antibodies Predict Response Durability to Nadofaragene Firadenovec Therapy in BCG-unresponsive Non-muscle-invasive Bladder Cancer: Secondary Analysis of a Phase 3 Clinical Trial

抗腺病毒抗体可预测对卡介苗无反应的非肌层浸润性膀胱癌患者接受纳多法拉根菲拉德诺韦克治疗的疗效持久性:一项3期临床试验的二次分析

Mitra, Anirban P; Narayan, Vikram M; Mokkapati, Sharada; Miest, Tanner; Boorjian, Stephen A; Alemozaffar, Mehrdad; Konety, Badrinath R; Shore, Neal D; Gomella, Leonard G; Kamat, Ashish M; Bivalacqua, Trinity J; Montgomery, Jeffrey S; Lerner, Seth P; Busby, J Erik; Poch, Michael; Crispen, Paul L; Steinberg, Gary D; Schuckman, Anne K; Downs, Tracy M; Svatek, Robert S; Mashni, Joseph; Lane, Brian R; Guzzo, Thomas J; Bratslavsky, Gennady; Karsh, Lawrence I; Woods, Michael E; Brown, Gordon A; Canter, Daniel; Luchey, Adam; Lotan, Yair; Krupski, Tracey; Inman, Brant A; Williams, Michael B; Cookson, Michael S; Keegan, Kirk A; Andriole, Gerald L; Sankin, Alexander I; Boyd, Alan; O'Donnell, Michael A; Philipson, Richard; Ylä-Herttuala, Seppo; Sawutz, David; Parker, Nigel R; McConkey, David J; Dinney, Colin P N